Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious ophthalmic co- morbidities. The greater myopia severity, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded with the goal of developing a proprietary, stable, low-dose atropine eyedrop to treat myopia progression in children and minimize the risk of ocular co-morbidities. Formulation Matters! At Sydnexis, we have focused on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic.
View Top Employees from SydnexisWebsite | https://www.sydnexis.com |
Employees | View employees |
Founded | 2014 |
Phone | (619) 507-9827 |
Industry | Pharmaceutical Manufacturing, Manufacturing, Drug Discovery, Pharmaceutical, Other Healthcare Technology Systems, Health Care |
Looking for a particular Sydnexis employee's phone or email?
2 people are employed at Sydnexis.
Sydnexis is based in Del Mar, California.